Loading clinical trials...
Loading clinical trials...
Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Conditions
Interventions
Methylprednisolone
Etoposide
+5 more
Locations
1
United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
Start Date
May 15, 2006
Primary Completion Date
October 15, 2018
Completion Date
October 15, 2018
Last Updated
September 4, 2019
NCT07388563
NCT06337318
NCT05529069
NCT06263491
NCT05139017
NCT07350863
Lead Sponsor
University of Arizona
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions